Coherus Oncology, Inc. (CHRS) vs Veraxa Biotech AG (VRXA)

Coherus Oncology, Inc. CHRS 1.00 −6.54%
Veraxa Biotech AG VRXA 1.11 +0.91%

Coherus Oncology, Inc. and Veraxa Biotech AG are both Biotechnology companies. Coherus Oncology, Inc. and Veraxa Biotech AG are of similar size ($165.3M and $162.5M).

Metric	CHRS	VRXA	Biotechnology median
P/E	n/m	—	8.50
P/S	3.04	—	9.71
P/B	2.54	—	2.13
Price to free cash flow	n/m	—	20.82
EV/EBITDA	n/m	—	0.64
EV/Sales	5.14	—	9.21
Earnings yield	(103.00%)	—	(33.15%)
Free cash flow yield	(120.77%)	—	(25.50%)

Metric	CHRS	VRXA	Biotechnology median
Gross margin	68.94%	—	65.16%
Operating margin	(311.56%)	—	0.00%
Net margin	(259.41%)	—	0.00%
Free cash flow margin	(365.22%)	—	0.00%
Return on equity	(146.27%)	—	(56.36%)
Return on assets	(41.90%)	—	(48.04%)
Return on invested capital	0.00%	—	0.00%

Metric	CHRS	VRXA	Biotechnology median
Revenue growth (TTM)	61.00%	—	6.02%
EPS growth (last fiscal year)	472.00%	—	30.26%
Revenue growth, 5-year CAGR	(38.41%)	—	9.41%
Net income growth, 5-year CAGR	4.91%	—	0.00%

Metric	CHRS	VRXA	Biotechnology median
Debt to equity	0.61	—	0.00
Current ratio	1.77	—	4.72
Net debt to EBITDA	0.76	—	0.96

Metric	CHRS	VRXA	Biotechnology median
Dividend yield	—	—	0.09%
Payout ratio	—	—	—

Metric	CHRS	VRXA	Biotechnology median
Market cap	165.32m	162.50m	135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack